Detalhe da pesquisa
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674077
2.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882206
3.
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
Br J Cancer
; 129(12): 2025-2033, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935787
4.
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Lancet Oncol
; 19(2): 249-256, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29326029
5.
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
Br J Cancer
; 118(5): 679-697, 2018 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29438365
6.
HER2-positive breast cancer.
Lancet
; 389(10087): 2415-2429, 2017 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27939064
7.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
Lancet
; 389(10075): 1195-1205, 2017 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28215665
8.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(6): 732-742, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526536
9.
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
Breast Cancer Res
; 19(1): 16, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183321
10.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Lancet Oncol
; 17(6): 791-800, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27179402
11.
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Br J Cancer
; 115(3): 290-6, 2016 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27404453
12.
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
Breast Cancer Res Treat
; 155(1): 127-32, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26708471
13.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Lancet
; 384(9938): 164-72, 2014 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24529560
14.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
N Engl J Med
; 367(19): 1783-91, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23020162
15.
The immune system and response to HER2-targeted treatment in breast cancer.
Lancet Oncol
; 15(2): e58-68, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24480556
16.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 15(6): 580-91, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24742739
17.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657003
18.
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
Breast Cancer Res
; 16(3): R50, 2014 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24887458
19.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet
; 382(9897): 1021-8, 2013 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23871490
20.
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Invest New Drugs
; 32(6): 1188-96, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24898305